The results of combination therapy were comparatively analyzed in 60 patients with human papillomavirus (HPV)-associated cervical neoplasias. Thirty patients in the study group were given the antiviral and immunomodulatory drug - intravenous and intravaginal panavir before destructive treatment. Thirty patients in the control group had traditional destructive treatment. It has been ascertained that the use of systemic and local combination antiviral therapy before destructive treatments enhances the efficiency of the therapy performed, promotes a reduction in process relapsing, and leads to HPV elimination in 85% of cases.